Form 4: Iovance Biotherapeutics Chief Medical Officer Reports Stock Transactions

Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, reported the vesting of restricted stock units and subsequent tax withholding.

Summary

• Friedrich Graf Finckenstein, the Chief Medical Officer of Iovance Biotherapeutics, reported transactions involving the company's stock on January 14, 2025.
• 2,813 restricted stock units (RSUs) vested, converting into common stock.
• 1,578 shares were withheld by the company to cover tax obligations related to the vesting of the RSUs.
• Following these transactions, Mr. Finckenstein directly owns 63,886 shares of Iovance Biotherapeutics common stock.

Sentiment

Score: 7

Explanation: The document reflects routine insider transactions related to executive compensation. It is a neutral event with no significant positive or negative implications for the company's performance.

Industry Context

This is a routine filing related to executive compensation and is common for publicly traded companies. It provides transparency into the stock ownership of key personnel.

Comparison to Industry Standards

• Stock-based compensation, including RSUs, is a common practice in the biotechnology industry to incentivize and retain key executives.
• The vesting schedule and tax withholding practices are standard procedures for RSU grants.
• Similar filings are regularly made by executives at comparable companies such as Kite Pharma, Juno Therapeutics, and Adaptimmune.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect the standard vesting of executive compensation.
• The tax withholding ensures compliance with tax regulations.

Key Dates

Keywords

Iovance Biotherapeutics, IOVA, Friedrich Graf Finckenstein, restricted stock units, RSU, stock transaction, insider trading, Form 4, Chief Medical Officer